Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed and Refractory Multiple Myeloma (RRMM)”

156 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 156 results

Large-scale testing (Phase 3)Looking for participantsNCT07579234
What this trial is testing

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Shandong New Time Pharmaceutical Co., LTD 261
Testing effectiveness (Phase 2)Looking for participantsNCT06822972
What this trial is testing

HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Duke University 27
Large-scale testing (Phase 3)Looking for participantsNCT05519085
What this trial is testing

Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Celgene 810
Not applicableLooking for participantsNCT06285318
What this trial is testing

Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

Who this might be right for
Relapsed/Refractory Multiple Myeloma (RRMM)
Janssen-Cilag Ltd. 900
Testing effectiveness (Phase 2)Ended earlyNCT04824794
What this trial is testing

GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)Diffuse Large B Cell Lymphoma (DLBCL)Acute Myeloid Leukemia (AML)
Genmab 130
Early research (Phase 1)Looking for participantsNCT07715630
What this trial is testing

In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Chongqing Precision Biotech Co., Ltd 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT07150104
What this trial is testing

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 14
Large-scale testing (Phase 3)Looking for participantsNCT05730036
What this trial is testing

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals 410
Early research (Phase 1)WithdrawnNCT05918250
What this trial is testing

MRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT05972135
What this trial is testing

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Who this might be right for
Multiple Myeloma
SCRI Development Innovations, LLC 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT02406222
What this trial is testing

Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
University of Leeds 124
Testing effectiveness (Phase 2)Looking for participantsNCT07266441
What this trial is testing

JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 157
Early research (Phase 1)Study completedNCT01749969
What this trial is testing

SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients

Who this might be right for
Plasma Cell Myeloma
Sanofi 57
Large-scale testing (Phase 3)Active Not RecruitingNCT04162210
What this trial is testing

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 325
Testing effectiveness (Phase 2)Study completedNCT02045017
What this trial is testing

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

Who this might be right for
Multiple Myeloma
Celgene 81
Early research (Phase 1)Study completedNCT02616640
What this trial is testing

Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 114
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07348393
What this trial is testing

A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Assistance Publique - Hôpitaux de Paris 70
Large-scale testing (Phase 3)Active Not RecruitingNCT05028348
What this trial is testing

Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Who this might be right for
Multiple Myeloma
European Myeloma Network B.V. 117
Testing effectiveness (Phase 2)WithdrawnNCT05408026
What this trial is testing

Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Alliance Foundation Trials, LLC.
Large-scale testing (Phase 3)Study completedNCT04939142
What this trial is testing

Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Antengene Corporation 154
Next Page